CanSense aims to change lives through the early detection of bowel cancer using spectroscopy and AI technologies on a standard blood test, helping to detect cancer early when still treatable and curable. ProblemColorectal cancer (CRC) is the UK’s second-deadliest cancer, with most cases diagnosed late and 54% considered preventable. Current pathways like the FIT test suffer from low uptake, poor accuracy and long delays, especially harming underserved communities, where CRC mortality is 83% higher in the most deprived areas. Earlier, more accessible diagnostics are urgently needed. An accurate blood test could transform early detection, reduce healthcare inequalities and save lives. Primary care is vital, yet limited by the lack of acceptable, scalable testing.Solution CanSense delivers a revolutionary blood test using laser spectroscopy and AI to detect bowel cancer early, with 95.7% sensitivity. Unlike faecal tests or colonoscopy, it’s non-invasive, cost-effective and patient-preferred. It accurately detects cancer and even the pre-cursors to cancer, polyps, enabling earlier diagnosis, fewer unnecessary referrals and faster clinical decision-making. Designed for primary care, it can support the NHS goal to detect 75% of cancers early, improves patient experience and reduces disparities in access and outcomes across diverse population. MarketCanSense addresses a €7.8B European CRC diagnostics market, with potential to reach a €200B global cancer diagnostics market by enabling scalable, label-free blood testing for CRC and future multi-cancer screening.ContactCanSense LinkedInCanSense website This article was published on 2025-09-17
